Spotlight on Dermatology

Credits: 1.00 CME
Clinical Reflections®: The Learning Pathway in Atopic Dermatitis: Maximizing Positive Outcomes for Your Patients
Jonathan Silverberg, MD, PhD, MPH
Postgraduate Institute for Medicine

Clinical Reflections®: The Learning Pathway in Atopic Dermatitis: Maximizing Positive Outcomes for Your Patients

Start

Activity Details

Free CME
1.0 AMA PRA Category 1 Credit
Released: June 28, 2018
Expires: June 27, 2019
1 hour

Target Audience

US-based dermatology and allergy/immunology clinicians who manage patients with atopic dermatitis (AD)

Learning Objectives

After completing this activity, the participant will demonstrate the ability to:

  1. Apply current principles of pathophysiology of atopic dermatitis (AD) and the concept of atopic march to therapeutic approaches to disease management
  2. Develop treatment plans for patients with AD that reflect evidence-based guidelines, use of new and emerging therapeutic options, and strategies to optimize short-term control and long-term management of the disease
  3. Assess for and manage quality-of-life issues and psychosocial comorbidities in patients with AD
  4. Utilize shared decision making and develop treatment plans that will result in high levels of adherence and better patient outcomes

Jointly Provided By

This activity is jointly provided by Postgraduate Institute for Medicine and RMEI Medical Education, LLC.

Faculty

Jonathan I. Silverberg, MD, PhD, MPH (Chair)
Associate Professor, Dermatology, Preventive Medicine, and Medical Social Sciences
Northwestern University Feinberg School of Medicine
Director, Northwestern Medicine Multidisciplinary Eczema Center
Director, Patch Testing Clinic
Northwestern Memorial Hospital
Chicago, IL

Jonathan I. Silverberg, MD, PhD, MPH, has affiliations with AbbVie, Anaptysbio, Asana, Eli Lilly, Galderma, Glenmark, Kiniksa, LEO Pharma Inc., Menlo Therapeutics Inc., Pfizer, Realm, Regeneron-Sanofi, and Roivant (Consulting Fees); Regeneron-Sanofi (Speakers’ Bureau); and Galderma, GlaxoSmithKline, and Regeneron-Sanofi (Contracted Research).


Emma Guttman, MD, PhD
Professor of Dermatology, Sol and Clara Kest
Icahn School of Medicine at Mount Sinai
New York, NY

Emma Guttman, MD, PhD, has affiliations with AbbVie, Allergan, Almirall, Amgen, Anacor, AnaptyBio, Asana Biosciences, BMS, Celgene, Curadim, Dermira, Drais, Eli Lilly, Escalier, Galderma, Glenmark, Kiowa Kirin, Kymab Limited, Lead Pharma, LEO Pharma Inc., Medimmune, Novartis, Pfizer, Regeneron, Sanofi, Sienna, Stiefel/GlaxoSmithKline, Theravance, and Vitae (Consultant).


Eric Simpson, MD, MCR
Professor of Dermatology, Department of Dermatology
Oregon Health & Science University
Portland, OR

Eric Simpson, MC, MCR, has affiliations with AbbVie, Eli Lilly, LEO Pharma Inc., Menlo Therapeutics Inc., Pfizer, Regeneron, and Sanofi Genzyme (Consulting Fees); Eli Lilly, Glaxo Smith Kline, LEO Pharma Inc., Novartis, Regeneron Pharmaceuticals, Inc., and Roivant (Contracted Research).

Disclosure of Conflicts of Interest

The Postgraduate Institute for Medicine (PIM) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflict of interest (COI) they may have as related to the content of this activity. All identified COI are thoroughly vetted and resolved according to PIM policy. PIM is committed to providing its learners with high quality CME activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial interest.

Joint Accreditation Statement

Accreditation Council for Pharmacy EducationIn support of improving patient care, this activity has been planned and implemented by the Postgraduate Institute for Medicine and RMEI Medical Education, LLC. The Postgraduate Institute for Medicine is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Physician Continuing Medical Education

The Postgraduate Institute for Medicine designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

How to Receive Credit

By reviewing the course content and successfully completing the post-test and evaluation, physicians are entitled to receive up to 1.0 AMA PRA Category 1 Credit(s)™. A statement of credit will be available to print from your user history page. Users must:

  • Read the learning objectives and faculty disclosures.
  • Participate in the activity.
  • Complete the activity evaluation.
Physicians who successfully complete the post-test and evaluation will receive CME credit. You must score 75% or higher on the post-test to receive credit for this activity. All other participants who successfully complete the post-test and evaluation will receive a certificate of participation. If you would like to contact Postgraduate Institute for Medicine, please email information@pimed.com.

Commercial Support

This activity is jointly provided by Postgraduate Institute for Medicine and RMEI Medical Education, LLC. This activity is supported by an educational grant from Sanofi Genzyme and Regeneron Pharmaceuticals.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patients' conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer's product information, and comparison with recommendations of other authorities.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications. The opinions expressed in this educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Course Viewing Requirements

Supported Browsers:
Internet Explorer 8.0+ for Windows 2003, Vista, XP, Windows 7, Windows 8.1 and above
Google Chrome 28.0+ for Windows, Mac OS, or Linux
Mozilla Firefox 23.0+ for Windows, Mac OS, or Linux
Safari 6.0+ for Mac OSX 10.7 and above

Supported Phones & Tablets:
Android 4.0.3 and above
iPhone/iPad with iOS 6.1 or above.

Dermatology Presentations

0.75 CME
Penn State College of Medicine
Examining the Crucial Coalition Between Dermatology and Rheumatology in Psoriatic Arthritis Treatment: Early Collaboration in the Treatment of PsA

Examining the Crucial Coalition Between Dermatology and Rheumatology in Psoriatic Arthritis Treatment: Early Collaboration in the Treatment of PsA

Start

Provided By

Activity Details

Free CME
0.75 AMA PRA Category 1 Credits
Released: October 6, 2017
Expires: October 6, 2018
45 minutes to complete

Target Audience

Rheumatologists, dermatologists, and allied health care professionals involved in the treatment of patients with psoriasis and PsA.

Learning Objectives

Upon completion of this educational activity, the participant should be able to:

  • Screen patients with psoriasis for inflammatory arthritides such as PsA.
  • Describe the consequences of delaying rheumatology referral of patients with psoriasis who have PsA.
  • Discuss the complementary skills and experience that a dermatologist and rheumatologist can each bring to the care of a patient with PsA.
  • Describe effective methods of inter-specialty communication that facilitate co-management of psoriasis patients with PsA.

Activity Description

Psoriatic arthritis (PsA) is a serious, inflammatory arthritis associated with psoriasis and multiple comorbidities that often goes undiagnosed and untreated. This activity will examine strategies for early recognition and referral, as well as specialty collaboration in the treatment of PsA.

Faculty

Eric M. Ruderman, MD
Professor of Medicine
Associate Chief, Clinical Affairs
Division of Rheumatology
Northwestern University
Feinberg School of Medicine
Chicago, IL

Dr. Ruderman has disclosed the following:
Consultant/Advisor: AbbVie, Amgen, BMS, Celltrion, Janssen, Lilly, Novartis, Pfizer
Research Grant: Pfizer


Joseph F. Merola, MD, MMSc
Assistant Professor of Medicine
Harvard Medical School
Director, Clinical Unit for Research Innovation and Trials (CUReIT)
Co-Director, Center for Skin and Related Musculoskeletal Diseases
Departments of Dermatology and Medicine
Division of Rheumatology
Brigham and Women's Hospital
Boston, MA

Dr. Merola has disclosed the following:
Speakers Bureau: AbbVie
Consultant/Advisor: AbbVie, Amgen, Biogen, GSK, Janssen, Kiniksa, Lilly, Mallinckrodt, Momenta, Novartis, Pfizer, Samumed, Sanofi, Science 37, UCB


Conflict of Interest Policy/Disclosure Statement

It is our policy to ensure balance, independence, objectivity, and scientific rigor in all of our educational programs. Faculty and course directors have disclosed relevant financial relationships with commercial companies, and Penn State has a process in place to resolve any conflict of interest.

Penn State staff involved in the development and review of this activity have nothing to disclose.

MCM Education staff involved in the development and review of this activity have nothing to disclose.

Accreditation Statement

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Penn State College of Medicine and MCM Education. Penn State College of Medicine is accredited by the ACCME to provide continuing medical education for physicians.

Credit Designation Statement

Penn State College of Medicine designates this enduring activity for a maximum of 0.75 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Instructions for Receiving Credit

  • Click "Start Program"
  • Take the pre-test
  • Review the activity
  • Take the post-test and score 80%
  • You are allowed a total of 3 attempts
  • Complete the evaluation
  • View, print, or save a CME certificate verifying your credit/participation in this activity

Statement of Commercial Support

This activity is supported by independent educational grants from Novartis and AbbVie.

Disclaimer Statement/Disclosure of Unlabeled Use

The opinions expressed in this educational activity are those of the faculty and do not necessarily reflect the opinions or recommendations of their affiliated institutions; the publisher; Penn State College of Medicine; Novartis; or AbbVie. Any medications, diagnostic procedures, or treatments discussed by the program presenters should not be used by clinicians or other health care professionals without first evaluating their patients’ conditions, considering possible contraindications or risks, reviewing any applicable manufacturer’s product information, and comparing any therapeutic approach with the recommendations of other authorities.

Faculty members are required to inform the audience when they are discussing off-label or unapproved uses of devices or drugs. Devices or drugs that are still undergoing clinical trials are identified as such and should not be portrayed as standard, accepted therapy. Please consult full prescribing information before using any product mentioned in this activity. If using products in an investigational, off-label manner, it is the responsibility of the prescribing physician to monitor the medical literature to determine recommended dosages and uses of the drugs. Neither the publisher nor the providers promote the use of any agent outside of approved labeling.

Contact Information for Questions About the Activity

MCM Education
17 Blacksmith Road
Suite 100
Newtown, PA 18940
info@cmecorner.com

Hardware/Software Requirements

Computer Requirements: Minimum System Requirements: • Pentium III, 600 MHz or Equivalent Processor • 512 MB of RAM • Windows XP, Vista, or 7 • Mac OS X • 800x600 Monitor Resolution • 16-bit Color • 16 bit Sound Card with Speakers

1.00 CME
Postgraduate Institute for Medicine
Clinical Reflections®: The Learning Pathway in Atopic Dermatitis: Maximizing Positive Outcomes for Your Patients

Clinical Reflections®: The Learning Pathway in Atopic Dermatitis: Maximizing Positive Outcomes for Your Patients

Start

Activity Details

Free CME
1.0 AMA PRA Category 1 Credit
Released: June 28, 2018
Expires: June 27, 2019
1 hour

Target Audience

US-based dermatology and allergy/immunology clinicians who manage patients with atopic dermatitis (AD)

Learning Objectives

After completing this activity, the participant will demonstrate the ability to:

  1. Apply current principles of pathophysiology of atopic dermatitis (AD) and the concept of atopic march to therapeutic approaches to disease management
  2. Develop treatment plans for patients with AD that reflect evidence-based guidelines, use of new and emerging therapeutic options, and strategies to optimize short-term control and long-term management of the disease
  3. Assess for and manage quality-of-life issues and psychosocial comorbidities in patients with AD
  4. Utilize shared decision making and develop treatment plans that will result in high levels of adherence and better patient outcomes

Jointly Provided By

This activity is jointly provided by Postgraduate Institute for Medicine and RMEI Medical Education, LLC.

Faculty

Jonathan I. Silverberg, MD, PhD, MPH (Chair)
Associate Professor, Dermatology, Preventive Medicine, and Medical Social Sciences
Northwestern University Feinberg School of Medicine
Director, Northwestern Medicine Multidisciplinary Eczema Center
Director, Patch Testing Clinic
Northwestern Memorial Hospital
Chicago, IL

Jonathan I. Silverberg, MD, PhD, MPH, has affiliations with AbbVie, Anaptysbio, Asana, Eli Lilly, Galderma, Glenmark, Kiniksa, LEO Pharma Inc., Menlo Therapeutics Inc., Pfizer, Realm, Regeneron-Sanofi, and Roivant (Consulting Fees); Regeneron-Sanofi (Speakers’ Bureau); and Galderma, GlaxoSmithKline, and Regeneron-Sanofi (Contracted Research).


Emma Guttman, MD, PhD
Professor of Dermatology, Sol and Clara Kest
Icahn School of Medicine at Mount Sinai
New York, NY

Emma Guttman, MD, PhD, has affiliations with AbbVie, Allergan, Almirall, Amgen, Anacor, AnaptyBio, Asana Biosciences, BMS, Celgene, Curadim, Dermira, Drais, Eli Lilly, Escalier, Galderma, Glenmark, Kiowa Kirin, Kymab Limited, Lead Pharma, LEO Pharma Inc., Medimmune, Novartis, Pfizer, Regeneron, Sanofi, Sienna, Stiefel/GlaxoSmithKline, Theravance, and Vitae (Consultant).


Eric Simpson, MD, MCR
Professor of Dermatology, Department of Dermatology
Oregon Health & Science University
Portland, OR

Eric Simpson, MC, MCR, has affiliations with AbbVie, Eli Lilly, LEO Pharma Inc., Menlo Therapeutics Inc., Pfizer, Regeneron, and Sanofi Genzyme (Consulting Fees); Eli Lilly, Glaxo Smith Kline, LEO Pharma Inc., Novartis, Regeneron Pharmaceuticals, Inc., and Roivant (Contracted Research).

Disclosure of Conflicts of Interest

The Postgraduate Institute for Medicine (PIM) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflict of interest (COI) they may have as related to the content of this activity. All identified COI are thoroughly vetted and resolved according to PIM policy. PIM is committed to providing its learners with high quality CME activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial interest.

Joint Accreditation Statement

Accreditation Council for Pharmacy EducationIn support of improving patient care, this activity has been planned and implemented by the Postgraduate Institute for Medicine and RMEI Medical Education, LLC. The Postgraduate Institute for Medicine is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Physician Continuing Medical Education

The Postgraduate Institute for Medicine designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

How to Receive Credit

By reviewing the course content and successfully completing the post-test and evaluation, physicians are entitled to receive up to 1.0 AMA PRA Category 1 Credit(s)™. A statement of credit will be available to print from your user history page. Users must:

  • Read the learning objectives and faculty disclosures.
  • Participate in the activity.
  • Complete the activity evaluation.
Physicians who successfully complete the post-test and evaluation will receive CME credit. You must score 75% or higher on the post-test to receive credit for this activity. All other participants who successfully complete the post-test and evaluation will receive a certificate of participation. If you would like to contact Postgraduate Institute for Medicine, please email information@pimed.com.

Commercial Support

This activity is jointly provided by Postgraduate Institute for Medicine and RMEI Medical Education, LLC. This activity is supported by an educational grant from Sanofi Genzyme and Regeneron Pharmaceuticals.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patients' conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer's product information, and comparison with recommendations of other authorities.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications. The opinions expressed in this educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Course Viewing Requirements

Supported Browsers:
Internet Explorer 8.0+ for Windows 2003, Vista, XP, Windows 7, Windows 8.1 and above
Google Chrome 28.0+ for Windows, Mac OS, or Linux
Mozilla Firefox 23.0+ for Windows, Mac OS, or Linux
Safari 6.0+ for Mac OSX 10.7 and above

Supported Phones & Tablets:
Android 4.0.3 and above
iPhone/iPad with iOS 6.1 or above.

0.75 CME
Postgraduate Institute for Medicine
Optimizing Management Approaches in Patients with Moderate-to-Severe Atopic Dermatitis

Optimizing Management Approaches in Patients with Moderate-to-Severe Atopic Dermatitis

Start

Activity Details

Free CME
0.75 AMA PRA Category 1 Credit
Released: March 27, 2018
Expires: March 27, 2019
0.75 hour to complete

Jointly Provided By

Target Audience

Dermatology clinicians who manage patients with moderate-to-severe atopic dermatitis (AD)

Learning Objectives

After completing this activity, the participant will demonstrate the ability to:

  1. Apply current principles of pathophysiology of atopic dermatitis and the concept of atopic march to therapeutic approaches to disease management
  2. Develop treatment plans for patients with atopic dermatitis that reflect evidence-based guidelines, use of new therapeutic options, and strategies to optimize short-term control and long-term management of the disease
  3. Address quality-of-life issues and psychosocial comorbidities in managing patients with atopic dermatitis
  4. Utilize shared decision making and develop treatment plans that will result in high levels of adherence and better patient outcomes

Activity Description

Recent developments in the treatment of moderate-to-severe atopic dermatitis (AD) have changed the way in which we are able to manage the disease. This interactive case-based educational program allows you to meet 3 patients in an AD clinic, make management decisions, compare your responses with those of your peers, and learn from the experts about best management approaches.

Faculty

Mark Lebwohl, MD (Chair)
Kimberly and Eric J. Waldman Professor of Dermatology
Icahn School of Medicine at Mount Sinai
Chairman, Kimberly and Eric J. Waldman Department of Dermatology
Mount Sinai Health System
New York, NY


Emma Guttman, MD, PhD
Professor of Dermatology, Sol and Clara Kest
Icahn School of Medicine at Mount Sinai
New York, NY


David M. Pariser, MD, FACP, FAAD
Professor of Dermatology
Eastern Virginia Medical School
Virginia Clinical Research
Pariser Dermatology Specialists
Norfolk, VA


Disclosure of Conflicts of Interest

Postgraduate Institute for Medicine (PIM) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflict of interest (COI) they may have as related to the content of this activity. All identified COI are thoroughly vetted and resolved according to PIM policy. PIM is committed to providing its learners with high quality CME activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial interest.

The faculty reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME activity:

  • Mark Lebwohl, MD, is an employee of Mount Sinai which receives research funds from: Abbvie, Amgen, Boehringer Ingelheim, Celgene, Eli Lilly, Janssen/Johnson & Johnson, Kadmon, Medimmune/Astra Zeneca, Novartis, Pfizer, Valeant, and ViDac; Allergan, Aqua Leo-pharma, and Promius (Consultant)
  • Emma Guttman, MD, PhD, has affiliations with AbbVie, Allergan, Almirall, Amgen, Anacor, AnaptyBio, Asana Biosciences, BMS, Celgene, Curadim, Dermira, Eli Lilly, Escalier, Galderma, Glenmark, Kiowa Kirin, Kymab, LEO Pharmaceuticals, Medimmune, Novartis, Pfizer, Regeneron, Sanofi, Sienna, Theravance, and Vitae (Consultant)
  • David M. Pariser, MD, FACP, FAAD, has affiliations with Bickel Biotechnology, Biofrontera AG, Celegene, Dermira, DUSA Pharmaceuticals, LEO Pharmaceuticals, Novartis, Promius, Regeneron, Sanofi, TheraVida, and Valeant (Consultant); Pfizer (Advisory Board); Abbott Laboratories, Amgen, Asana Biosciences, Bickel Biotechnology, Celgene, Dermavant Sciences, Eli Lilly, LEO Pharmaceuticals, Merck, Novartis, Novo Nordisk, Ortho Dermatologics, Peplin, Photocure, Promius, Regeneron, Stiefel, and Valeant (Contracted Research).

RMEI Medical Education, LLC

  • Jacqui Brooks, MBBCh, MRCPsych, has no affiliations with commercial interests to disclose.
  • Misha Mutizwa, MD, has affiliations with Celgene (Consulting Fees).
  • Sharon Powell, has no affiliations with commercial interests to disclose.       

Postgraduate Institute for Medicine
The following PIM planners and managers: Judi Smelker-Mitchek, MBA, MSN, RN; Trace Hutchison, PharmD; Samantha Mattiucci, PharmD, CHCP; and Jan Schultz, MSN, RN, CHCP, have nothing to disclose.

Joint Accreditation Statement

Accreditation Council for Pharmacy EducationIn support of improving patient care, this activity has been planned and implemented by the Postgraduate Institute for Medicine and RMEI Medical Education, LLC. Postgraduate Institute for Medicine is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Physician Continuing Medical Education

The Postgraduate Institute for Medicine designates this enduring material for a maximum of 0.75 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

How to Receive Credit

By reviewing the course content and successfully completing the post-test and evaluation, physicians/DOs are entitled to receive up to 0.75 AMA PRA Category 1 Credit(s)™. A statement of credit will be available to print from your user history page. Users must:

  • Read the learning objectives and faculty disclosures.
  • Participate in the activity.
  • Complete the activity evaluation.

Physicians/DOs who successfully complete the post-test and evaluation will receive CME credit. You must score 75% or higher on the post-test to receive credit for this activity. All other participants who successfully complete the post-test and evaluation will receive a certificate of participation.

Commercial Support

This activity is jointly provided by Postgraduate Institute for Medicine and RMEI Medical Education, LLC. This activity is supported by an educational grant from Sanofi Genzyme and Regeneron Pharmaceuticals.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patients' conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer's product information, and comparison with recommendations of other authorities.

Technical Support

For any technical issues or issues with your CME Certificate, please visit: http://www.realcme.com/cms/support-center.

Course Viewing Requirements

Supported Browsers:
Internet Explorer 8.0+ for Windows 2003, Vista, XP, Windows 7, Windows 8.1 and above
Google Chrome 28.0+ for Windows, Mac OS, or Linux
Mozilla Firefox 23.0+ for Windows, Mac OS, or Linux
Safari 6.0+ for Mac OSX 10.7 and above

Supported Phones & Tablets:
Android 4.0.3 and above
iPhone/iPad with iOS 6.1 or above